Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$1.05 - $2.85 $22,102 - $59,992
-21,050 Reduced 59.83%
14,133 $17,000
Q2 2022

Aug 12, 2022

BUY
$0.63 - $2.96 $1,178 - $5,535
1,870 Added 5.61%
35,183 $63,000
Q1 2022

May 16, 2022

SELL
$1.43 - $3.14 $715 - $1,570
-500 Reduced 1.48%
33,313 $67,000
Q4 2021

Feb 14, 2022

SELL
$2.7 - $4.76 $7,263 - $12,804
-2,690 Reduced 7.37%
33,813 $92,000
Q3 2021

Nov 15, 2021

SELL
$4.06 - $5.8 $90,058 - $128,655
-22,182 Reduced 37.8%
36,503 $163,000
Q2 2021

Aug 13, 2021

SELL
$5.02 - $7.05 $159,234 - $223,626
-31,720 Reduced 35.09%
58,685 $340,000
Q1 2021

May 14, 2021

BUY
$4.81 - $10.34 $162,698 - $349,750
33,825 Added 59.78%
90,405 $635,000
Q4 2020

Feb 12, 2021

BUY
$4.13 - $6.41 $100,470 - $155,936
24,327 Added 75.43%
56,580 $272,000
Q3 2020

Nov 09, 2020

BUY
$4.82 - $7.72 $49,766 - $79,709
10,325 Added 47.09%
32,253 $188,000
Q2 2020

Aug 13, 2020

BUY
$5.69 - $9.69 $124,770 - $212,482
21,928 New
21,928 $148,000
Q3 2018

Nov 14, 2018

SELL
$29.37 - $49.48 $150,462 - $253,486
-5,123 Closed
0 $0
Q2 2018

Aug 14, 2018

SELL
$42.06 - $62.4 $14,216 - $21,091
-338 Reduced 6.19%
5,123 $233,000
Q1 2018

May 15, 2018

BUY
$50.12 - $67.72 $109,462 - $147,900
2,184 Added 66.65%
5,461 $288,000
Q4 2017

Feb 14, 2018

BUY
$57.69 - $84.58 $40,959 - $60,051
710 Added 27.66%
3,277 $223,000
Q3 2017

Nov 14, 2017

BUY
$67.17 - $84.81 $15,046 - $18,997
224 Added 9.56%
2,567 $212,000
Q2 2017

Aug 14, 2017

BUY
N/A
2,343
2,343 $219,000

Others Institutions Holding CLVS

# of Institutions
1
Shares Held
166
Call Options Held
0
Put Options Held
0

About Clovis Oncology, Inc.


  • Ticker CLVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 144,480,000
  • Market Cap $13M
  • Description
  • Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...
More about CLVS
Track This Portfolio

Track Lpl Financial LLC Portfolio

Follow Lpl Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lpl Financial LLC with notifications on news.